# US 2025/0152532 A1 · Vigabatrin liquid pharmaceutical composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152532 A1
- Document ID: US20250152532A1
- Status: Published application
- Kind: A1
- Application number: 18/806,581
- Filed: 2024-08-15
- Published: 2025-05-15
- Earliest claimed: 2022-09-16
- Assignees: Pyros Pharmaceuticals, Inc.
- Applicants: Pyros Pharmaceuticals, Inc.
- Inventors: Nrupa PATEL; Raenel V. GIBSON; Michael M. SMITH; Edwin URRUTIA
- Web page: https://patentgrep.com/patent/US20250152532A1

## CPC

- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61J 1/1468: {Containers characterised by specific material properties}
- A61J 7/0053: {Syringes, pipettes or oral dispensers}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The embodiments of the present invention relate to a stable liquid vigabatrin pharmaceutical compositions in the liquid form of a solution. Particularly, the stable vigabatrin liquid pharmaceutical composition is manufactured as a ready-to-use industrialized premixture that does not require reconstitution or dilution prior to administration to a patient. The vigabatrin liquid pharmaceutical composition is stable six months or longer at room temperature and has levels of total impurities and Vigabatrin-related compound A that are both not more than 0.04% at, or prior to, six months. In some embodiments, the composition has improved stability and patient compliance. In some embodiments, the compositions may be advantageous for the patients having swallowing difficulties or when the patients are unable to take solid oral dosage forms. In some embodiments, the composition improves compliance with ketogenic diet.

## Claims

### Claim 1

A ready-to-drink liquid pharmaceutical composition consisting of: vigabatrin, or a pharmaceutically acceptable salt thereof, in the range from about 0.1 wt % to about 20 wt %; at least one preservative in the range from about 0.001 wt % to about 1.0 wt %; at least one sweetening agent in the range from about 0.05 wt % to about 40.0 wt %; at least one flavoring agent in the range from about 0.001 wt % to about 10.0 wt %, and quantum satis (q.s.) purified water; wherein the ready-to-drink liquid pharmaceutical composition:
(i) is a ready to use premixture that does not require reconstitution or dilution prior to administration to a patient; and
(ii) is stable for at least twenty four months at room temperature or refrigerated conditions, and wherein total impurities due to degradation are not more than 0.05%.

### Claim 2 (depends on 1)

The ready-to-drink vigabatrin liquid pharmaceutical composition of claim 1, wherein the liquid pharmaceutical composition is free of buffering agents, antioxidants, and solubilizers.

### Claim 3 (depends on 1)

The ready-to-drink vigabatrin liquid pharmaceutical composition of claim 1, wherein the ready-to-drink liquid pharmaceutical composition further has levels of vigabatrin-related compound A due to degradation not more than 0.05% at or prior to twenty four months.

### Claim 4 (depends on 1)

The ready-to-drink vigabatrin liquid pharmaceutical composition of claim 1, wherein the ready-to-drink liquid pharmaceutical composition is packaged in a glass, plastic or metal container.

### Claim 5 (depends on 1)

The ready-to-drink vigabatrin liquid pharmaceutical composition of claim 1, wherein the ready-to-drink liquid pharmaceutical composition comprises: 0.1125-0.1375 wt % methylparaben, 0.01125-0.01375 wt % propylparaben, 0.225-0.275 wt % sucralose, 0.0027-0.0033 wt % peppermint flavor, and g.s. purified water.

### Claim 6 (depends on 1)

The ready-to-drink vigabatrin liquid pharmaceutical composition of claim 1, wherein the vigabatrin, or the pharmaceutically acceptable salt thereof, is about 10 wt %.

### Claim 7 (depends on 1)

The ready-to-drink vigabatrin liquid pharmaceutical composition of claim 1, wherein the vigabatrin, or the pharmaceutically acceptable salt thereof, is 10 wt %.

### Claim 8

A ready-to-drink vigabatrin liquid pharmaceutical composition consisting of:
(i) 10 wt % vigabatrin or a pharmaceutically acceptable salt thereof;
(ii) 0.125 wt % methylparaben;
(iii) 0.0125 wt % propylparaben;
(iv) 0.25 wt % sucralose;
(v) 0.003 wt % flavor; and
(vi) q.s. purified water;
wherein the ready-to-drink liquid pharmaceutical composition does not require reconstitution or dilution prior to administration to a patient and is stable up to at least twenty four months at room temperature and refrigerated conditions, and wherein total impurities due to degradation are not more than 0.05%.

### Claim 9 (depends on 8)

The ready-to-drink vigabatrin liquid pharmaceutical composition of claim 8, wherein the ready-to-drink liquid pharmaceutical composition is free of buffering agents, antioxidants, and solubilizers.

### Claim 10 (depends on 8)

The ready-to-drink vigabatrin liquid pharmaceutical composition of claim 8, wherein the ready-to-drink liquid pharmaceutical composition further has levels of vigabatrin-related compound A due to degradation not more than 0.05% at, or prior to, twenty four months.

### Claim 11 (depends on 8)

The ready-to-drink vigabatrin liquid pharmaceutical composition of claim 8, wherein the ready-to-drink liquid pharmaceutical composition is packaged in a glass, plastic or metal container.

### Claim at position 12

12-20. (canceled)

### Claim 21

A pre-manufactured liquid pharmaceutical composition formulated for ready-to-drink oral delivery,
wherein the pre-manufactured liquid pharmaceutical composition comprises about 0.1 wt % to about 20 wt % active pharmaceutical ingredient (API); at least one preservative in the range from about 0.001 wt % to about 1.0 wt %; at least one sweetening agent in the range from about 0.05 wt % to about 40.0 wt %; at least one flavoring agent in the range from about 0.001 wt % to about 10.0 wt %, and quantum satis (q.s.) purified water;
wherein the API consists of vigabatrin or a pharmaceutically acceptable salt thereof;
wherein the pre-manufactured liquid pharmaceutical composition is capable of being provided to a patient as a ready to use premixture that does not require reconstitution or dilution prior to administration to a patient; and
wherein the pre-manufactured liquid pharmaceutical composition is stable, wherein levels of vigabatrin-related compound A due to degradation and/or total impurities due to degradation are not more than 0.05% for at least twenty four months at room temperature or refrigerated conditions.

### Claim 22 (depends on 21)

The pre-manufactured liquid pharmaceutical composition of claim 21, wherein a single dose to the patient of the pre-manufactured liquid pharmaceutical composition includes from zero to five carbohydrate calories.

### Claim 23 (depends on 21)

The pre-manufactured liquid pharmaceutical composition of claim 21, wherein the pre-manufactured liquid pharmaceutical composition lacks a nutritive/digestible/glycemic carbohydrate after administration to the patient.

### Claim 24 (depends on 21)

The pre-manufactured liquid pharmaceutical composition of claim 21, wherein the pre-manufactured liquid pharmaceutical composition does not contain a digestible carbohydrate and is operative to reduce carbohydrate craving in the patient thereby promoting compliance with a ketogenic diet.

### Claim 25 (depends on 24)

The pre-manufactured liquid pharmaceutical composition of claim 24, wherein said reducing carbohydrate craving and the promoting compliance in the patient each include a period of time in the range from more than one week to over a period of months.

### Claim 26 (depends on 21)

The pre-manufactured liquid pharmaceutical composition of claim 21, wherein at least one sweetener consists of a zero-calorie sweetener.

### Claim 27 (depends on 21)

The pre-manufactured liquid pharmaceutical composition of claim 21, wherein the pre-manufactured liquid pharmaceutical composition comprises: 0.1125-0.1375 wt % methylparaben, 0.01125-0.01375 wt % propylparaben, 0.225-0.275 wt % sucralose, 0.0027-0.0033 wt % peppermint flavor, and purified water.

### Claim 28 (depends on 21)

The pre-manufactured liquid pharmaceutical composition of claim 21, wherein the vigabatrin, or the pharmaceutically acceptable salt thereof, is about 10 wt %.

### Claim 29 (depends on 21)

The pre-manufactured liquid pharmaceutical composition of claim 21, wherein the vigabatrin, or the pharmaceutically acceptable salt thereof, is 10 wt %.
